Delivery Order SPE2DB22D9239-SPE2DB25FDJ46

Award Date 5/13/25
Potential Completion Date 6/4/25
Potential Value $87K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $87,418.08 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award covers the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through February 10, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of Xenpozyme 20 mg vials, a specialized pharmaceutical product, with a ceiling value of $92,733.12 and a period of performance through January 27, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) under the SPE2DB program. The contract is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a ceiling value of $109,272.60 and a period of performance through June 4, 2024. DMS Pharmaceutical Group is a pharmaceutical wholesaler that provides a wide range of pharmaceutical products and medical supplies to support the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $87,418.08, is for the supply of 4567363691 XENPOZYME 20 MG VIALS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $87,418.08 firm fixed-price contract is for the delivery of XENPOZYME 20 MG VIALS, with a completion date of June 11, 2025. The contract is not set aside for any specific business category. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through November 6, 2024. DMS Pharmaceutical Group is a key supplier for the DLA, holding a $499,999,999 Indefinite Delivery Contract to...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is a delivery order worth $87,418.08 for the supply of 4567903324 - XENPOZYME 20 MG VIALS, a specialized pharmaceutical product. The contract is a firm fixed-price arrangement with an ultimate completion date of April 23, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract has a potential value of $109,272.60 and a completion date of March 7, 2024. DMS Pharmaceutical Group will provide XENPOZYME 20 MG VIALS to fulfill the agency's pharmaceutical supply needs. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with DLA,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $145,696.80 award is for the delivery of XENPOZYME 20 MG VIALS, a pharmaceutical product, with a completion date of January 17, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS and has an ultimate completion date of April 15, 2024. This delivery order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, contract 4600082013 under the SPE2DB program, which is valued at up...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDJ46
    Delivery Order

This is a firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of XENPOZYME 20 MG VIALS, with a ceiling value of $87,418.08 and a period of performance through June 4, 2025.

DMS Pharmaceutical Group Inc. is an established pharmaceutical wholesaler that has secured a significant Indefinite Delivery Contract (IDC) valued at $499,999,999 with the DLA under the SPE2DB program. This IDC enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, in support of the medical supply needs of military health facilities worldwide.

The contract award does not have a set-aside designation, allowing DMS Pharmaceutical Group to compete effectively in the federal procurement market as a woman-owned small business.

Generated 8/12/25, 11:48 AM